Comparative evaluation of efficacy, pharmacodynamics, and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Ltd.) and reference adalimumab (Humira®, Abbvie Inc.) in patients with active rheumatoid arthritis on concomitant methotrexate therapy

Abstract Background Our study aimed to compare efficacy and safety of Hetero’s adalimumab (Mabura®, Hetero Biopharma Limited) versus reference adalimumab (Humira®, Abbvie Inc.) in Indian patients with active rheumatoid arthritis (RA) concomitant on methotrexate (MTX) therapy. Methods Patients (n = 1...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Shubhadeep Sinha, Biswadip Ghosh, Syamasis Bandyopadhyay, Firdaus Fatima, Vamsi Krishna Bandi, Pankaj Thakur, Bala Reddy, Sreenivasa Chary, Leela Talluri, Ajay Gupta, Amit Ramchandra Kale, Anil Kumar Gupta, Ashok Kumar P, Diwakar Reddy, Younus Mohammed, Soma Shekar, Sudheer T, Vijay G. Goni, Vishnu Sharma, Vishwanath Yeligod
Formato:	Artigo
Idioma:	Inglês
Publicado em:	BMC 2020-06-01
coleção:	BMC Rheumatology
Assuntos:	Rheumatology Adalimumab Methotrexate Antirheumatic agents
Acesso em linha:	http://link.springer.com/article/10.1186/s41927-020-00124-9
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!